Veracyte

About Veracyte

Veracyte is a global cancer diagnostics company that develops molecular tests to assess the unique biology of individual patient tumors and help clinicians make personalized treatment decisions. The company offers laboratory-developed tests (LDTs) for thyroid, prostate, bladder, and lung cancers, as well as the Prosigna Breast Cancer Prognostic Gene Signature Assay available as a CE-IVD test outside the US. Their molecular tests help answer critical questions in cancer care, such as whether patients can avoid unnecessary surgery, whether monitoring is appropriate instead of immediate treatment, and which treatments will be most effective. Veracyte operates CLIA-certified, high-complexity clinical labs in San Diego, San Francisco, and Austin, and has benefited over 800,000 patients with their genomic tests. The company's platform is supported by over 600 peer-reviewed publications validating its clinical utility.